Zografos L, Gailloud C, Perret C, Uffer S, Raimondi S, Chamot L, Carrel S, Greiner R
Clinique Ophtalmologique Universitaire de Lausanne.
Klin Monbl Augenheilkd. 1988 May;192(5):572-8. doi: 10.1055/s-2008-1050181.
A great number of techniques are currently available for the conservative treatment of uveal melanomas: ocular applicators emitting gamma rays 60Co, 125I) or high-energy beta rays (106Ru/106Rh), light photocoagulation, surgical excision, and accelerated proton beam irradiation. Life expectancy following conservative treatment is equal to or better than that following enucleation. This is demonstrated by nonrandomized comparative studies, and by the authors' own long-term results following the conservative treatment of melanomas by 60Co applicators: mortality due to metastases of small melanomas was 3% (V = smaller than 10 x 10 x 3 mm), with medium-size melanomas it was 12% (V = 10 x 10 x 3-15 x 15 x 5 mm), and with large melanomas 21% (V = larger than 15 x 15 x 5 mm). Accelerated proton beam irradiation of uveal melanomas is currently the method of choice for the conservative treatment of uveal melanomas. The sharp boundaries of the irradiated zone, the uniformly distributed irradiation dose, and beam-splitting are the main advantages of this technique. During the last three years, 310 cases of uveal melanoma have been treated in Switzerland with an accelerated proton beam. Of these, 214 were followed up for more than one year. Eight patients (3.9%) died of metastases. Visual acuity was identical or superior to initial visual acuity in 60.3% of the cases, while 39.6% exhibited a deterioration of vision or a functional loss. Favorable results achieved by conservative treatment of uveal melanomas considerably limited the indications for enucleation, which is now only performed in exceptional situations.
发射γ射线(60Co、125I)或高能β射线(106Ru/106Rh)的眼部敷贴器、光凝、手术切除以及加速质子束照射。保守治疗后的预期寿命等于或优于眼球摘除后的预期寿命。这在非随机对照研究以及作者自身使用60Co敷贴器对黑色素瘤进行保守治疗的长期结果中得到了证实:小黑色素瘤(V = 小于10×10×3mm)转移导致的死亡率为3%,中等大小黑色素瘤(V = 10×10×3 - 15×15×5mm)为12%,大黑色素瘤(V = 大于15×15×5mm)为21%。加速质子束照射目前是葡萄膜黑色素瘤保守治疗的首选方法。该技术的主要优点是照射区域边界清晰、照射剂量分布均匀以及束流分裂。在过去三年中,瑞士使用加速质子束治疗了310例葡萄膜黑色素瘤。其中,214例随访超过一年。8例患者(3.9%)死于转移。60.3%的病例视力与初始视力相同或优于初始视力,而39.6%的病例视力下降或出现功能丧失。葡萄膜黑色素瘤保守治疗取得的良好结果大大限制了眼球摘除的适应症,现在仅在特殊情况下进行。